Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Overview
Amisulpride (DAN 2163) (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.
Chemical Properties
| Molecular Formula | C17H27N3O4S |
| Molecular Weight | 369.48 |
| CAS Numbers | 71675-85-9 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(NCC1N(CC)CCC1)(=O)C2=C(OC)C=C(N)C(S(CC)(=O)=O)=C2 |
Storage and Handling
0C Short Term, -20C Long Term
References
Rosenzweig P, et al. Hum Psychopharmacol. 2002 Jan;17[1] 1-13.